Evaluation of the potential impact of age- and gender-specific pharmacokinetic differences on tissue dosimetry.
about
Physiologically based pharmacokinetic modeling of persistent organic pollutants for lifetime exposure assessment: a new tool in breast cancer epidemiologic studiesAging and the environment: a research frameworkApproaches for assessing risks to sensitive populations: lessons learned from evaluating risks in the pediatric populationReverse dosimetry: interpreting trihalomethanes biomonitoring data using physiologically based pharmacokinetic modeling.Physiologically based pharmacokinetic (PBPK) modeling of interstrain variability in trichloroethylene metabolism in the mouse.Studying permethrin exposure in flight attendants using a physiologically based pharmacokinetic modelApparent half-lives of dioxins, furans, and polychlorinated biphenyls as a function of age, body fat, smoking status, and breast-feedingLevels of persistent organic pollutant and their predictors among young adults.Physiologically based pharmacokinetic modeling: methodology, applications, and limitations with a focus on its role in pediatric drug development.Distributions of Autocorrelated First-Order Kinetic Outcomes: Illness Severity.Modeling the Human Kinetic Adjustment Factor for Inhaled Volatile Organic Chemicals: Whole Population Approach versus Distinct Subpopulation ApproachReview and analysis of inhalation dosimetry methods for application to children's risk assessment.Computational pharmacokinetics during developmental windows of susceptibility.Addressing Early Life Sensitivity Using Physiologically Based Pharmacokinetic Modeling and In Vitro to In Vivo Extrapolation.The Food and Drug Administration Office of Women's Health: Impact of Science on Regulatory Policy: An Update.Whole-body physiologically based pharmacokinetic models.Approaches for applications of physiologically based pharmacokinetic models in risk assessment.Challenges in the application of quantitative approaches in risk assessment: a case study with di-(2-ethylhexyl)phthalate.An improved model to predict physiologically based model parameters and their inter-individual variability from anthropometry.Characterization of the human kinetic adjustment factor for the health risk assessment of environmental contaminants.Assessment of health risks resulting from early-life exposures: Are current chemical toxicity testing protocols and risk assessment methods adequate?Evolution of chemical-specific adjustment factors (CSAF) based on recent international experience; increasing utility and facilitating regulatory acceptance.Physiologically based pharmacokinetic model for quinocetone in pigs and extrapolation to mequindox.Modeling Pharmacokinetics.Have physiologically-based pharmacokinetic models delivered?Approaches to acrylamide physiologically based toxicokinetic modeling for exploring child-adult dosimetry differences.Dosimetric adjustments for interspecies extrapolation of inhaled poorly soluble particles (PSP).High perceived sensitivity to medicines is associated with higher medical care utilisation, increased symptom reporting and greater information-seeking about medication.Human blood concentrations of cotinine, a biomonitoring marker for tobacco smoke, extrapolated from nicotine metabolism in rats and humans and physiologically based pharmacokinetic modeling.Clinical relevance of predictive physiologically based pharmacokinetic methods.Sex differences in urinary levels of several biological indicators of exposure: a simulation study using a compartmental-based toxicokinetic model.Age-dependent partition coefficients for a mixture of volatile organic solvents in Sprague-Dawley rats and humans.Modern methodologies and tools for human hazard assessment of chemicalsA framework and case studies for evaluation of enzyme ontogeny in children's health risk evaluation.Organ growth functions in maturing male Sprague-Dawley rats.Carbaryl and 1-naphthol tissue levels and related cholinesterase inhibition in male Brown Norway rats from preweaning to senescence.Linking fate model in freshwater and PBPK model to assess human internal dosimetry of B(a)P associated with drinking water.Options for incorporating children's inhaled dose into human health risk assessment.Perchlorate and radioiodide kinetics across life stages in the human: using PBPK models to predict dosimetry and thyroid inhibition and sensitive subpopulations based on developmental stage.Characterizing uncertainty and variability in physiologically based pharmacokinetic models: state of the science and needs for research and implementation.
P2860
Q24644907-F24B61F3-64E8-4BA5-88FC-E1B9F37FB32DQ24815677-26273E88-9E86-4C21-98E7-858C61A0F3A0Q28389663-D1A489EF-3C9A-4A9D-AB6E-A38C50270CB8Q31077784-F2596467-A3E2-4F3A-AB0B-74A2BF330E60Q33585007-4713D7B7-10F8-4AE3-A80C-A72FDC50EB44Q33777528-35FD94E5-E01D-486E-88F4-16B66310DB46Q34972720-685D0D8E-9850-4015-B4C9-DAE133612396Q34985280-308FAB24-6F47-40CB-B1A4-4A067C81931CQ35054518-3AF2696F-BC42-4F7F-8BD4-2C82F1846AE7Q35659714-5A32DB02-04D6-4858-B3E8-4472EC37D2D1Q35864881-3A1136EC-76F2-4DF7-ABDF-D83495E28F20Q36131290-9FF200EE-FE65-4475-A228-B6DCE0E5B8CFQ36195215-B5A8EC5B-4ECA-41A2-B7AC-93BB70B3978EQ36657666-7DA8042E-B35E-47C3-B01F-4C1B5BD2427FQ36683248-2067A8A1-1E96-47AF-B6D6-DF8B73D275C6Q36788418-F31B8FC0-3671-4C91-B9AF-6245F06D28D4Q37201545-85D70B32-3848-405E-BF41-08D2CF90C3A3Q37916566-AA7609A2-8AE8-455C-8AEC-96AC3D0DAA68Q38041230-F0838740-3A61-47A5-A699-F02BA65B64DCQ38137867-9918BB34-8B02-4AB1-BB56-34C1C974653FQ38357598-4DEA19A2-3E06-4CE4-A367-D8745C74C26DQ38691542-B88B7D0A-C9F6-4176-96FF-401C06AFB898Q39077905-58F72174-78B9-403B-9CB1-ADACB02C7D7FQ39677925-D7D84AFC-42DC-47FC-AE7A-10FD439D64BAQ39728369-9FFCC619-50D7-440F-9272-517ECD3C6280Q40148266-ACD1A9DB-3D37-428E-ABA4-B71F07E5CCDBQ40405326-98B4772B-9ADA-453C-ADFE-4E00CF31D0FEQ41103874-8376DAA7-9410-4810-9023-72082074B989Q42410356-B111B051-D031-47B9-A1CE-FE9AA2760FDCQ43998919-702D6D1C-CEC8-4EB6-AA9D-A3E4B9FE760DQ44368114-72A1DFDF-EAD0-4D4D-850A-E1EF13BAE2FCQ46988643-E49E8E04-68D2-478F-902E-7709F0C6ED07Q47154406-CC4B1B1B-EA4B-447A-B348-868DA89E508FQ47254105-5E95793B-EFF2-445A-ADC1-D0730B77DDE6Q48190885-D1450FE2-111B-4E69-AAB7-CCEFE26B625BQ48844032-654074B6-4F45-40B1-924B-3062FB35A6AAQ51161726-56375D40-E949-4FA4-809E-BED16D8C90AFQ51690519-5932BD1E-D164-4AD5-A1C3-620EAD733F92Q51988108-82108710-03FA-4D6C-A553-E97F5B6182B9Q53236816-DCA61858-778F-4626-B528-75B1DFB577CB
P2860
Evaluation of the potential impact of age- and gender-specific pharmacokinetic differences on tissue dosimetry.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Evaluation of the potential im ...... fferences on tissue dosimetry.
@en
Evaluation of the potential im ...... fferences on tissue dosimetry.
@nl
type
label
Evaluation of the potential im ...... fferences on tissue dosimetry.
@en
Evaluation of the potential im ...... fferences on tissue dosimetry.
@nl
prefLabel
Evaluation of the potential im ...... fferences on tissue dosimetry.
@en
Evaluation of the potential im ...... fferences on tissue dosimetry.
@nl
P2093
P2860
P356
P1476
Evaluation of the potential im ...... fferences on tissue dosimetry.
@en
P2093
Harvey J Clewell
P Robinan Gentry
Ramesh Sarangapani
Tammie R Covington
P2860
P304
P356
10.1093/TOXSCI/KFH109
P577
2004-03-31T00:00:00Z